id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-263753-p3evgngz	Magoon, Rohan	Dexmedetomidine in COVID-19: probing promises with prudence!	2020-10-27		.txt	text/plain	462	28	44	While the peak DEX-doses >0.8 µg/kg/hr and daily cumulative DEX-doses >12.9 µg/kg/day have been described to be associated with an elevated withdrawal incidence [7] , lack of presentation of the contextual DEXdose administered in the COVID-19 patient featured in the Stockton and Kyle-Sidell case-report, captivates attention [1] . (iii) In addition, once on invasive mechanical ventilation, a precision approach to sedation in COVID-19 patients, as epitomized by Payen et al, appears to be prudent centralising the focus on inter-individual variability and synchronizing the level of ventilator support to the subsequent target of sedation, thereby directing the subsequent choice of sedative agents, including DEX [8, 9] . Dexmedetomidine and worsening hypoxemia in the setting of COVID-19: A case report Dexmedetomidine-Associated Hyperpyrexia in Three Critically Ill Patients With Coronavirus Disease Incidence of dexmedetomidine withdrawal in adult critically Ill patients: a pilot study Sedation for critically ill patients with COVID-19: Which specificities?	./cache/cord-263753-p3evgngz.txt	./txt/cord-263753-p3evgngz.txt